Akorn Institutional ownership
What is the Institutional ownership of Akorn?
The Institutional ownership of Akorn, Inc. is 75.93%
What is the definition of Institutional ownership?
Institutional Ownership is the amount of a company’s available stock owned by mutual or pension funds, insurance companies, investment firms, endowments or other large entities that manage funds on the behalf of others.
Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.
Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.
Institutional ownership of companies in the Health Care sector on OTC compared to Akorn
What does Akorn do?
Akorn, Inc., a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Further, the company sells its products to wholesale distributors. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. On May 20, 2020, Akorn, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Companies with institutional ownership similar to Akorn
- Glenveagh Properties Plc has Institutional ownership of 75.89%
- Golar LNG has Institutional ownership of 75.89%
- Golar Lng has Institutional ownership of 75.89%
- Ted Baker Plc has Institutional ownership of 75.89%
- Penn Virginia has Institutional ownership of 75.90%
- Squarespace has Institutional ownership of 75.92%
- Akorn has Institutional ownership of 75.93%
- Baring Emerging Europe Plc has Institutional ownership of 75.93%
- NovoCure Ltd has Institutional ownership of 75.94%
- Custom Truck One Source Inc has Institutional ownership of 75.94%
- Summit Securities has Institutional ownership of 75.95%
- Pets At Home Plc has Institutional ownership of 75.96%
- MetLife has Institutional ownership of 75.98%